Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00241345 · ClinicalTrials.gov registry record · Phase 3
Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant
A Phase 3 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 3
- Development phase
- 39
- Enrollment target
NCT00241345 is a Phase 3 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 39 participants.
The verdict
NCT00241345, a Phase 3 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine if preemptive therapy with oral valganciclovir is as effective as intravenous ganciclovir in clearing cytomegalovirus (CMV) viremia as determined by quantitative CMV polymerase chain reaction (PCR) assay in patients who have undergone bone marrow or peripheral blood stem cell transplant.
Interventions
- DRUG Valganciclovir
- DRUG Ganciclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2004-06 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00241345
The ClinicalTrials.gov registry entry for NCT00241345 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Valganciclovir is the first listed.
NCT00241345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00241345 about?
NCT00241345 is a clinical study titled "Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant". The purpose of this trial is to determine if preemptive therapy with oral valganciclovir is as effective as intravenous ganciclovir in clearing cytomegalovirus (CMV) viremia as determined by quantitative CMV polymerase chain reaction (PCR) assay in patients who have undergone bone marrow or peripher...
What is the current status of trial NCT00241345?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 39 participants. The study started on 2004-06. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00241345?
The interventions under investigation include: Valganciclovir (DRUG), Ganciclovir (DRUG).
Who is sponsoring clinical trial NCT00241345?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.